Elevated CCL2 levels and CCR2 signaling have been implicated in this process, suggesting that targeting the CCL2–CCR2 axis may offer a novel therapeutic approach to attenuate monocyte-driven inflammation in COPD [41]. The gene discussed is CCR2; the disease is chronic obstructive pulmonary disease.